Psyence BioMed unit signs term sheet with PsyLabs for exclusive U.S. ibogaine license, supply deal
Bitget2026/09/28 11:01- Psyence Biomedical entered a binding term sheet with PsyLabs for exclusive U.S. rights to pharmaceutical-grade ibogaine via its Texas unit.
- Texas Ibogaine Research Corporation would receive exclusive development, supply, wholesale distribution rights, subject to a definitive agreement by Nov. 30, 2026.
- PsyLabs would remain the exclusive supplier; the license includes manufacturing know-how, specifications, technical documentation for ibogaine hydrochloride.
- Consideration includes up to about USD 1.3 million in development and regulatory milestones for the first drug candidate.
- Additional economics include a low single-digit royalty on net sales, an annual exclusivity fee after first FDA approval, and margin-sharing on resale.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CNN Enters Generative AI Partnership with Google
US Stock Market Movement | Nvidia-backed AI pharmaceutical company Iambic Therapeutics (IAM.US) debuts on Nasdaq, surging over 11% after opening
As of press time, the stock is up more than 11%, trading at $17.77.
US Stock Market Movement | 3D Printing Materials Supplier Amaero (AMRO.US) Debuts on US Stock Market, Trading Halt Triggered After Opening
Amaero, a manufacturer specializing in titanium and refractory metal powders for 3D printing in the defense and aerospace sectors, has gone public on the US stock market.
Crypto prices
More
